Abstract
An alarming rise in prescription and non-prescription misuse of opioids has been observed recently, leading to potentially devastating consequences. Opioid misuse contributes to cardiac risk burden and can cause diseases such as acute coronary syndrome, congestive heart failure, arrhythmias, QTc prolongation, and endocarditis. Here, we describe the case of a 35-year-old male with recreational fentanyl use who was found to have a cardiogenic shock on point-of-care ultrasound (POCUS), likely due to fentanyl-induced cardiomyopathy. Opioid-induced cardiomyopathy without any underlying cardiac disease in an adult appears to be a rare case. Our case highlights the importance of promptly recognizing fentanyl toxicity, screening for possible cardiomyopathy secondary to its use, and emergent resuscitation with the maintenance of ventilation, diuretics, and vasopressor support. The use of the reversal agent, naloxone, is a crucial part of management.
Keywords: rare side effect, fentanyl analogs, cardiac arrythmia, opioid use disorders, cardio toxicity
Introduction
Opioids are a class of substances that are used vastly in medicine for acute pain, anesthesia, and chronic non-cancer pain. They have a myriad of effects such as analgesia, sedation, respiratory depression, euphoria, miosis, constipation, pruritus, dependence, and tolerance [1,2]. Recently, there has been an alarming rise in both prescription and illicit use of these controlled substances. Highly addictive potential has led to an increase in fatal side effects and overdose-related deaths [1-4].
Cardiovascular medicine has also been affected by this opioid epidemic and a rise in cardiac diseases such as acute coronary syndrome, congestive heart failure, arrhythmias, QTc prolongation, and endocarditis is being associated with opioid misuse or overdose [5-8]. Along these lines, we report a peculiar case of cardiomyopathy caused by illicit fentanyl use, a drug that does not appear to be a commonly reported cause of drug-induced cardiomyopathy in adults. We came across one pediatric case report mentioning a very similar case [9].
Case presentation
A 35-year-old male presented to our hospital’s emergency department after being found unresponsive in bed by his father. He was reported to be last seen normal at 10 pm the night prior. Emergency medical services administered 2mg of Narcan® with resultant awakening. At bedside, the patient was lethargic but awake, oriented, and conversant. He voiced no acute complaints and denied any chest pain, palpitations, or shortness of breath. The patient endorsed nonprescription fentanyl use the previous night, both via inhalation and oral routes. He denied any other kind of recent substance use.
Past medical history was notably positive for psoriasis treated with adalimumab infusions, chronic back pain, and opioid use disorder with oxycodone for which he underwent rehabilitation. Social history was positive for current cigarette smoking with eight pack years (0.5 packs per day for 15 years) and weekly consumption of three to four alcoholic beverages. The patient denied having multiple sexual partners, lived with his father and two sons, and was self-employed.
Initial vital signs were temperature of 97.5oF, tachycardia of 126 beats per minute, tachypnea of 28 breaths per minute, oxygen saturation of 85% on room air, and hypotension to 67/48 mmHg (calculated mean arterial pressure (MAP) 54). On physical examination, the patient was drowsy but arousable, alert, and oriented to time, place, and person. Pupils were reactive and constricted to 3mm equally. Skin findings included multiple tattoos and erythematous patches with silvery scales on bilateral knees consistent with psoriasis. Chest auscultation had regular tachycardia with no murmurs whereas lung auscultation had clear air entry bilaterally with no appreciable crackles or wheezing. Abdomen was non-tender and non-distended. Lower extremity edema was absent. Laboratory test results are given in Table 1.
Table 1. Initial laboratory test results.
WBC: white blood count; BUN: blood urea nitrogen; pro-BNP: N-terminal prohormone of brain natriuretic peptide; TSH: thyroid-stimulating hormone; CPK: creatinine phosphokinase; pCO2: partial pressure of carbon dioxide; pO2: partial pressure of oxygen; FiO2: fraction of inspired oxygen
| Hematology | ||
| Name | Result | Reference Range |
| WBC | 6.8 | 3.5 - 10.8 K/ul |
| Hemoglobin | 14.5 | 11.5 - 15.5 g/dl |
| Hematocrit | 42.4 | 34.5 - 45.0 % |
| Platelet Count | 214 | 150 - 400 K/ul |
| General Chemistry | ||
| Name | Result | Reference Range |
| Sodium | 135 | 136 - 145 mmol/L |
| Potassium | 4.0 | 3.3 - 5.1 mmol/L |
| Chloride | 99 | 98 - 107 mmol/L |
| Bicarbonate | 33 | 22 - 29 mmol/L |
| BUN | 9 | 8 - 23 mg/dl |
| Creatinine | 1.0 | 0.7 - 1.2 mg/dl |
| Glucose | 110 | 74 - 109 mg/dl |
| Magnesium | 1.3 | 1.6 - 2.6 mg/dl |
| Phosphorus | 3.5 | 2.5 - 4.5 mg/dl |
| pro-BNP | 347 | 1 - 125 pg/ml |
| TSH | 0.500 | 0.27 - 4.2 uIU/ml |
| Cardiac Enzymes | ||
| Name | Result | Reference Range |
| Troponin T | 59 → 57 → 46 | <14 ng/L |
| CPK | 8279 | 120 - 180 U/L |
| Arterial Blood Gas | ||
| pH | 7.25 | 7.38 - 7.46 |
| pCO2 | 41 | 32 - 46 mmHg |
| pO2 | 160 | 74 - 108 mmHg |
| O2 saturation | 99 | 92 - 96 % |
| FiO2 | 100 | 21 - 100 % |
| Urine Toxicology | ||
| Amphetamine metabolites | Negative | Negative |
| Barbiturates | Negative | Negative |
| Benzodiazepines | Negative | Negative |
| Cannabinoids | Negative | Negative |
| Cocaine | Negative | Negative |
| Opioids | Positive | Negative |
| Fentanyl metabolite | 292 | <10 ng/mL |
| Phencyclidine | Negative | Negative |
EKG showed normal sinus rhythm, QTc of 423ms, and no ST-T wave abnormalities ( Figure 1).
Figure 1. Unremarkable EKG demonstrating normal sinus rhythm and no ST-T wave abnormalities. QTc: 423ms.
Chest x-ray showed bilateral infiltrates involving both right and left peri-hilar regions and lower lobes. No cardiomegaly was appreciated. Bedside POCUS was notably positive for B-line pattern, severe global left ventricular dysfunction, ejection fraction (EF) was 15-20%, and left ventricular outflow tract velocity time integral (LVOT VTI) was 7.7cm.
The patient was, therefore, admitted to ICU for cardiogenic shock possibly from fentanyl-induced cardiomyopathy and acute hypoxic respiratory failure from cardiogenic pulmonary edema requiring noninvasive positive pressure ventilation. Emergent resuscitation included noninvasive positive pressure ventilation, administration of furosemide 20mg intravenous push, and norepinephrine vasopressor peripherally. However, hypotension was refractory despite maximal dosing of 30 mcg/min. Therefore, central venous catheter and arterial line were inserted and dobutamine was started for inotropic support at 5 µg/kg/min with a brisk response in MAP to greater than 65. Transthoracic echocardiography the next day revealed mild global hypokinesis of the left ventricle and right wall motion abnormality. EF recovered to 40-45%. The LV wall thickness was normal, diastolic function was indeterminate and there was no valvular abnormality. Due to wall motion abnormalities and mild hypokinesis, cardiac catheterization via right radial artery was performed, which revealed right dominant anatomy with patent and normal coronary arteries. Left ventriculography showed apical tardokinesis and EF again at 40-45%. Vasopressors and noninvasive ventilation were successfully weaned off shortly after.
The patient was started on metoprolol succinate 25 mg daily and losartan 25 mg daily, counseled on drug and tobacco cessation, advised to follow up with cardiology within one week and obtain repeat echocardiography in eight weeks to reassess EF.
Discussion
Opioids are a common class of drugs in medicine that are used for a vast number of indications such as acute pain, anesthesia, chronic non-cancer pain, cough, diarrhea, and shortness of breath. These drugs act on the μ, κ, and δ opioid receptors found mainly in the central nervous system, peripheral nervous system, and gastrointestinal tract and induce a myriad of effects such as analgesia, sedation, respiratory depression, euphoria, miosis, constipation, pruritus, dependence, tolerance, etc.
Recently, there has been an alarming rise in both prescription and nonprescription use of these controlled substances. Highly addictive potential and fatal side effects have led to an increase in opioid-related overdose deaths; 68,000 deaths were reported in the US in 2020, which was 8.5 times the number of deaths in 1999 [1-4]. More than 70% of deaths occurred among males. People in the age group of 35-44 years and of non-Hispanic American Indian and Alaska Native ethnicity had the highest death rates. Understandably, cardiovascular medicine has also been affected by this opioid epidemic and a rise in cardiovascular diseases such as acute coronary syndrome, congestive heart failure, arrhythmias, QTc prolongation, and endocarditis is being associated with opioid overdose [5-8].
Mechanisms behind cardiovascular effects of opioid receptor agonism include bradycardia and vasodilation resulting in hypotension, orthostasis, syncope, and peripheral edema [2,8,10]. Conduction abnormalities stem from bradycardia as well as sodium, potassium, and calcium channel blockade [2,6,8,11,12,13]. The combination of these vascular and contractility anomalies leads to acute MI, arrhythmias, and other well-known complications of opioid misuse such as sudden death and cardiac and respiratory arrest [5,6,8]. Fentanyl is a synthetic opioid available most commonly in intravenous and transdermal formulations for analgesia, anesthesia, and sedation. Nowadays, it is also used as a recreational drug, mixed with other substances, for example, heroin, cocaine, benzodiazepines, or methamphetamine [1-4,14-16].
Our case is unique as it reports a rare occurrence of drug-induced cardiomyopathy from this opioid in the absence of any underlying cardiac disease. Fentanyl is well known for overdose deaths, usually from cardiopulmonary arrest when it is admixed with other drugs mentioned above [14-16]. As per our literature review, it does not appear to be a commonly reported direct cause of cardiomyopathy or acute onset heart failure with reduced EF (HFrEF) in adults. A pediatric case report with a similar presentation has been published in 2017 [9]. A thorough toxicology workup in our patient did not reveal co-ingestion of any other substance along with the fentanyl.
A brief summary of the commonly reported drugs associated with direct cardiomyotoxicity is given in Table 2.
Table 2. Commonly reported drugs associated with direct cardiomyotoxicity .
| Drug Class | Common example | Reference |
| Antimalarial | Chloroquine | Yogasundaram et al. [17] |
| Antiretroviral | Zidovudine | d'Amati et al. [18] |
| Antipsychotic | Clozapine | Rostagno et al. [19] |
| Anthracyclines | Doxorubicin | Steinherz et al. [20] |
| Monoclonal antibodies | Trastuzumab | Keefe et al. [21] |
| Tyrosine kinase inhibitors | Imatinib | Kerkelä et al. [22] |
| Alkylating agents | Cyclophosphamide | Gottdiener et al. [23] |
| Alcohol and cocaine are well-established causes of cardiomyopathy as well | ||
Usually, fentanyl or opioid overdose is a clinical diagnosis requiring prompt assessment and management. Common clinical features include altered mental status ranging from lethargy to coma, miosis, bradycardia, hypotension, and hypoxia. A unique feature specific to fentanyl is “wooden chest syndrome”, which involves rigidity of the abdominal muscles and diaphragm, inducing respiratory failure [24].
Diagnostic modalities include finger stick glucose check to rule out hypoglycemia, serum creatine phosphokinase (CPK) to rule out rhabdomyolysis from immobilization, Chest x-ray to check for possible aspiration, urine/serum toxicology screening, and EKG to assess QTc, especially in cases of a methadone overdose. Management centers on ensuring adequate ventilation via oxygen supplementation in case of spontaneous breathing. If the patient is apneic, then a bag valve mask may be used or intubation performed. Antidote therapy is crucial and comprises naloxone, which may be given IV or IM in 5-10 mg bolus dosing followed by infusion. Intranasal formulation is also available. An eventual psychiatric evaluation is recommended for possible suicidality.
Conclusions
Our case reports acute cardiomyopathy and HFrEF resulting from recreational fentanyl intoxication in a young male without prior history of cardiac disease. Acute fentanyl intoxication is an emerging problem in the United States healthcare system; therefore, it is important to recognize such rare complications from it. POCUS may serve as a quick and convenient tool to screen for possible cardiomyopathy in such cases of opioid overdose where clinical signs and symptoms of acute heart failure are evident. Resuscitation should be prompt and based on standard principles of heart failure management along with the administration of antidote naloxone to prevent mortality.
The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.
The authors have declared that no competing interests exist.
Human Ethics
Consent was obtained or waived by all participants in this study
References
- 1.CDC: Wide-ranging online data for epidemiologic research (WONDER) [ Jun; 2022 ];http://wonder.cdc.gov 2021
- 2.Opioid complications and side effects. Benyamin R, Trescot AM, Datta S, et al. https://www.painphysicianjournal.com/linkout?issn=1533-3159&vol=11&page=S105. Pain Physician. 2008;11:105–120. [PubMed] [Google Scholar]
- 3.Increases in drug and opioid-involved overdose deaths - United States, 2010-2015. Rudd RA, Seth P, David F, Scholl L. MMWR Morb Mortal Wkly Rep. 2016;65:1445–1452. doi: 10.15585/mmwr.mm655051e1. [DOI] [PubMed] [Google Scholar]
- 4.Trends and geographic patterns in drug and synthetic opioid overdose deaths - United States, 2013-2019. Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. http://dx.doi.org/10.15585/mmwr.mm7006a4. MMWR Morb Mortal Wkly Rep. 2021;70:202–207. doi: 10.15585/mmwr.mm7006a4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Frequency of cardiovascular events and in-hospital mortality with opioid overdose hospitalizations. Doshi R, Majmundar M, Kansara T, Desai R, Shah J, Kumar A, Patel K. Am J Cardiol. 2019;124:1528–1533. doi: 10.1016/j.amjcard.2019.07.068. [DOI] [PubMed] [Google Scholar]
- 6.High dose methadone and ventricular arrhythmias: a report of three cases. Walker PW, Klein D, Kasza L. Pain. 2003;103:321–324. doi: 10.1016/S0304-3959(02)00461-X. [DOI] [PubMed] [Google Scholar]
- 7.National trends in hospitalizations for stroke associated with infective endocarditis and opioid use between 1993 and 2015. Salehi Omran S, Chatterjee A, Chen ML, Lerario MP, Merkler AE, Kamel H. Stroke. 2019;50:577–582. doi: 10.1161/STROKEAHA.118.024436. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Cardiovascular complications of opioid use: JACC state-of-the-art review. Krantz MJ, Palmer RB, Haigney MC. J Am Coll Cardiol. 2021;77:205–223. doi: 10.1016/j.jacc.2020.11.002. [DOI] [PubMed] [Google Scholar]
- 9.Pediatric cardiac toxicity associated with fentanyl ingestion. Chuang R, Saleh F, Alyahya B. Toxicol Commun. 2018;2:39–41. [Google Scholar]
- 10.Brunton LL, Lazo JS, Parker KL. New York: McGraw-Hill; 2006. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. [Google Scholar]
- 11.The mode of action of several opioids on cardiac muscle. Wu C, Fry CH, Henry J. Exp Physiol. 1997;82:261–272. doi: 10.1113/expphysiol.1997.sp004021. [DOI] [PubMed] [Google Scholar]
- 12.Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. Katchman AN, McGroary KA, Kilborn MJ, Kornick CA, Manfredi PL, Woosley RL, Ebert SN. J Pharmacol Exp Ther. 2002;303:688–694. doi: 10.1124/jpet.102.038240. [DOI] [PubMed] [Google Scholar]
- 13.Opioids and cardiac arrhythmia: a literature review. Behzadi M, Joukar S, Beik A. Med Princ Pract. 2018;27:401–414. doi: 10.1159/000492616. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Fentanyl law enforcement submissions and increases in synthetic opioid-involved overdose deaths - 27 states, 2013-2014. Gladden RM, Martinez P, Seth P. MMWR Morb Mortal Wkly Rep. 2016;65:837–843. doi: 10.15585/mmwr.mm6533a2. [DOI] [PubMed] [Google Scholar]
- 15.Distribution of furanyl fentanyl and 4-ANPP in an accidental acute death: a case report. Martucci HF, Ingle EA, Hunter MD, Rodda LN. Forensic Sci Int. 2018;283:0–7. doi: 10.1016/j.forsciint.2017.12.005. [DOI] [PubMed] [Google Scholar]
- 16.Fatalities involving carfentanil and furanyl fentanyl: two case reports. Swanson DM, Hair LS, Strauch Rivers SR, et al. J Anal Toxicol. 2017;41:498–502. doi: 10.1093/jat/bkx037. [DOI] [PubMed] [Google Scholar]
- 17.Chloroquine-induced cardiomyopathy: a reversible cause of heart failure. Yogasundaram H, Hung W, Paterson ID, Sergi C, Oudit GY. ESC Heart Fail. 2018;5:372–375. doi: 10.1002/ehf2.12276. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Dilated cardiomyopathy in a zidovudine-treated AIDS patient. d'Amati G, Kwan W, Lewis W. Cardiovasc Pathol. 1992;1:317–320. doi: 10.1016/1054-8807(92)90042-M. [DOI] [PubMed] [Google Scholar]
- 19.Clozapine associated cardiomyopathy: a cluster of 3 cases. Rostagno C, Domenichetti S, Pastorelli F, Gensini GF. Intern Emerg Med. 2011;6:281–283. doi: 10.1007/s11739-010-0468-4. [DOI] [PubMed] [Google Scholar]
- 20.Cardiac toxicity 4 to 20 years after completing anthracycline therapy. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. JAMA. 1991;266:1672–1677. [PubMed] [Google Scholar]
- 21.Trastuzumab-associated cardiotoxicity. Keefe DL. Cancer. 2002;95:1592–1600. doi: 10.1002/cncr.10854. [DOI] [PubMed] [Google Scholar]
- 22.Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Kerkelä R, Grazette L, Yacobi R, et al. Nat Med. 2006;12:908–916. doi: 10.1038/nm1446. [DOI] [PubMed] [Google Scholar]
- 23.Cardiotoxicity associated with high-dose cyclophosphamide therapy. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Arch Intern Med. 1981;141:758–763. [PubMed] [Google Scholar]
- 24.Wooden chest syndrome: a case report of fentanyl-induced chest wall rigidity. Rosal NR, Thelmo FL Jr, Tzarnas S, DiCalvo L, Tariq S, Grossman C. J Investig Med High Impact Case Rep. 2021;9:23247096211034036. doi: 10.1177/23247096211034036. [DOI] [PMC free article] [PubMed] [Google Scholar]

